Novo Nordisk, CagriSema

Data on new Novo Nordisk obesity drug disappoints in trial, shares drop
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.
Novo Nordisk Shares Tumble 8% on CagriSema Weight Loss Miss
Novo Nordisk (NVO, Financial) shares fell 8% on Monday morning following disappointing Phase 3 trial results for its weight loss drug CagriSema. The Redefine 2 trial
Novo Nordisk's CagriSema: A Breakthrough in Weight Loss for Type 2 Diabetes
Novo Nordisk's new drug, CagriSema, showed promising results in reducing weight among overweight or obese type 2 diabetes patients. During the phase III REDEFINE 2 trial, participants experienced a 15.
Novo Nordisk trial with next-gen diabetes drug shows 15.7% weight loss but shares fall
Novo Nordisk said on Monday its experimental next-generation drug CagriSema helped overweight or obese patients with type 2 diabetes cut their weight by 15.7% after 68 weeks, but shares fell, likely on the lower-than-expected weight loss.
Novo Nordisk shares fall on latest trial results for new obesity drug
Novo’s share price fell 8 per cent on Monday, having previously dived in December after a late-stage trial of CagriSema in overweight or obese people without diabetes found they lost an average of 22.7 per cent of their body weight. That was only marginally ahead of results for Mounjaro, an existing rival treatment made by Eli Lilly.
Novo Nordisk's CagriSema: A Weight-Loss Hopeful Under Market Scrutiny
Novo Nordisk's trial results for CagriSema, a next-gen obesity and diabetes drug, showed a 15.7% weight reduction in overweight patients with type 2 diabetes. Despite promising outcomes, shares dropped due to lower-than-expected weight loss,
Novo Shares Fall After CagriSema Results in Diabetes Patients
Novo Nordisk A/S shares fell the most since December after the drugmaker’s next-generation shot CagriSema showed 15.7% weight loss in a clinical trial of people with diabetes.
MedCity News4d
Novo Nordisk’s Next-Gen Obesity Drug Disappoints Again With Lower Than Expected Weight Loss
The two main ingredients in this drug cannot be dissolved together, so it must be administered by an injection device with two chambers. Novo Nordisk’s manufacturing capacity for CagriSema is ...
Daily Mail1mon
Patients who took Ozempic 2.0 in clinical trial reveal its staggering results... and terrifying side effects
fatigue and brain fog she experiences in the 24 hours after her weekly CagriSema injection are so bad that she sometimes can't leave bed. She has, however, kept to the recommended dosing protocol ...
Viking Therapeutics: Signs Of Insufficient Differentiation In Obesity Treatment (Rating Downgrade)
Viking Therapeutics' plans to launch VK2735 with an auto-injector could delay regulatory approval. Click here to read why ...
BioSpace11d
Obesity Late-Comer AbbVie Inks Up to $2.2B Amylin Deal With Gubra
AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...